| March 2008 · Vol. 20, No. 03 UPDATE: HOW DEVELOPMENTS ARE CHANGING PATIENT CARE
CERVICAL DISEASE
2007 produced compelling evidence: The HPV vaccine is efficacious in virus-naïve women and HPV DNA testing has value as a screening tool
|
Fast Track
Three major studies found HPV testing, with or without cytology, to be superior to cytology alone
2006 consensus guidelines discourage the use of colposcopy in adolescents who have ASC-US and LSIL
HPV test methods that lack FDA approval may not produce findings consistent with approved methods
|
|
Thomas
C.
Wright,
MDDr. Wright is Professor of Pathology at Columbia University in New York City. He served as Chair of the 2006 Consensus Conference, convened by the American Society for Colposcopy and Cervical Pathology. He also helped author the 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities, the 2004 Interim Guidance for Use of HPV DNA Testing for Primary Screening, and the 2001 Bethesda System.
The author is a consultant to Merck & Co., Inc., GlaxoSmithKline, and Roche Molecular Diagnostics.
New data enhance our knowledge in two critical areas previously covered in this update: the human papillomavirus (HPV) vaccine and HPV DNA testing for cervical cancer screening.
|
